{"id":505329,"date":"2020-09-03T14:00:02","date_gmt":"2020-09-03T14:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=505329"},"modified":"2020-09-03T14:00:02","modified_gmt":"2020-09-03T14:00:02","slug":"hereditary-angioedema-market-size-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hereditary-angioedema-market-size-trends-epidemiology-forecast-till-2030_505329.html","title":{"rendered":"Hereditary Angioedema Market, Size, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hereditary Angioedema Market, Size, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Hereditary Angioedema Market, Size, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s  &#8220;Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Hereditary Angioedema , historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) resulting in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hereditary Angioedema&nbsp;Market Insight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-angioedema-market\" target=\"_blank\">Hereditary Angioedema Market Size in 7MM in 2017 was USD 1,741.75 million<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-angioedema-market\" target=\"_blank\">Hereditary Angioedema&nbsp;Market Drivers<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rising Prevalence<\/li>\n<li>Introduction of Oral Therapy<\/li>\n<li>Increase in R&amp;D<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Hereditary Angioedema&nbsp;Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Misdiagnosis and under-diagnosis<\/li>\n<li>High treatment Cost<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Hereditary Angioedema&nbsp;market overall has been segmented into two treatment strategies that are commonly used for HAE as on-demand therapies, which are taken to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible and further as long-term prophylaxis of attacks. Short-term (or periprocedural) prophylaxis treatment is taken before activities that are known to trigger attacks.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Over recent years, significant advances have been made about HAE management, and the potential is greater than ever before for affected patients to move closer to living a life that is not overshadowed by disease morbidity. A range of effective therapies have become available, and treatment can now be managed at home by most patients, even with injectable agents. A growing understanding of the underlying pathophysiology of HAE has facilitated the development of several targeted therapies, and ongoing progress in this area will likely continue to improve prophylactic options for HAE as well as refine the disease, particularly in recently identified subtypes with normal C1 inhibitor. Additional laboratory and clinical research may identify biomarkers useful in predicting clinical phenotypes and\/or response to various therapeutic agents.<\/p>\n<p style=\"text-align: justify;\">The landscape of therapeutic options for Hereditary Angioedema&nbsp;patients has changed dramatically in the last two decades. Ongoing research promises even greater change in the foreseeable future. Given the economic and psychosocial burdens for patients living with angioedema, effective therapies with novel mechanisms will offer more choices for patients and physicians, as well as provide greater flexibility in routes of administration.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hereditary-angioedema-market\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hereditary-angioedema-market\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Hereditary Angioedema<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Hereditary Angioedema<\/p>\n<p style=\"text-align: justify;\">4. Hereditary Angioedema : Market Overview at a Glance<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. Hereditary Angioedema Total Market Share (%) Distribution in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2. Hereditary Angioedema Total Market Share (%) Distribution in 2030<\/p>\n<p style=\"text-align: justify;\">5. Hereditary Angioedema : Disease Background and Overview<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.2. Sign and Symptoms&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.3. Pathophysiology&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.4. Risk Factors&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.5. Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Hereditary Angioedema Epidemiology and Patient Population<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1. Epidemiology Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.1. Hereditary Angioedema Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.4. United States Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.1. Hereditary Angioedema Epidemiology Scenario in the United States (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.5. EU-5 Country-wise Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.1. Germany Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.1.1. Hereditary Angioedema Epidemiology Scenario in Germany (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.2. France Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.2.1. Hereditary Angioedema Epidemiology Scenario in France (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.3. Italy Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.3.1. Hereditary Angioedema Epidemiology Scenario in Italy (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.4. Spain Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.4.1. Hereditary Angioedema Epidemiology Scenario in Spain (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.5. United Kingdom Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.5.1. Hereditary Angioedema Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.6. Japan Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.6.1. Hereditary Angioedema Epidemiology Scenario in Japan (2017-2030)<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.1. Hereditary Angioedema Treatment and Management<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.2. Hereditary Angioedema Treatment Algorithm&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Hereditary Angioedema Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.1. List of Marketed Products in the 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.4. Pivotal Clinical Trials<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.5. Summary of Pivotal Clinical Trial<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.1. Key Cross<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.5. Product Profile<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">13. Hereditary Angioedema : Seven Major Market Analysis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.2. Hereditary Angioedema Market Size in 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.3. Hereditary Angioedema Market Size by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1. United States: Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.1. Hereditary Angioedema Total Market Size in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.2. Hereditary Angioedema Market Size by Therapies in the United States<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2. EU-5 countries: Market Size and Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.3. Germany Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.1. Hereditary Angioedema Total Market Size in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.2. Hereditary Angioedema Market Size by Therapies in Germany<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.4. France Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.1. Hereditary Angioedema Total Market Size in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.2. Hereditary Angioedema Market Size by Therapies in France<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.5. Italy Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.1. Hereditary Angioedema Total Market Size in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.2. Hereditary Angioedema Market Size by Therapies in Italy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.6. Spain Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.1. Hereditary Angioedema Total Market Size in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.2. Hereditary Angioedema Market Size by Therapies in Spain<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.7. United Kingdom Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.1. Hereditary Angioedema Total Market Size in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.2. Hereditary Angioedema Market Size by Therapies in the United Kingdom<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.8. Japan Market Outlook<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.1. Japan Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.2. Hereditary Angioedema Total Market Size in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.3. Hereditary Angioedema Market Size by Therapies in Japan<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Hereditary Angioedema<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hereditary-angioedema-market-size-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hereditary-angioedema-market-size-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Hereditary Angioedema , historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hereditary-angioedema-market-size-trends-epidemiology-forecast-till-2030_505329.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-505329","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/505329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=505329"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/505329\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=505329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=505329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=505329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}